. AndersonJJWoelfferKEHoltzmanJJJacobsAM: Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg. 43:285–289, 2004. S1067251604004193 [pii] http://dx.doi.org/10.1053/j.jfas.2004.07.005
2.
. ArmasLAHollisBWHeaneyRP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 89:5387–5391, 2004. 89/11/5387 [pii] http://dx.doi.org/10.1210/jc.2004-0360
3.
. ArumSM: New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes. 15:508–513, 2008. 10.1097/MED.0b013e3283184017 01266029-200812000-00006 [pii]
4.
. Barrett-ConnorEMoscaLCollinsP: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 355:125–137, 2006. 355/2/125 [pii] http://dx.doi.org/10.1056/NEJMoa062462
5.
. Bischoff-FerrariHAGiovannucciEWillettWC: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 84:18–28, 2006. 84/1/18 [pii]
6.
. CanalisEGiustinaABilezikianJP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 357:905–916, 2007. 357/9/905 [pii] http://dx.doi.org/10.1056/NEJMra067395
7.
. ChesnutCH3rd.SilvermanSAndrianoK: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 109:267–276, 2000. S0002934300004903 [pii]
. GarneroPHausherrEChapuyMC: Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 11:1531–1538, 1996.
12.
. GehrigLLaneJO'ConnorMI: Osteoporosis: management and treatment strategies for orthopaedic surgeons. J Bone Joint Surg Am. 90:1362–1374, 2008. 90/6/1362 [pii]
13.
. GennariC: Analgesic effect of calcitonin in osteoporosis. Bone. 30:67S–70S, 2002. S8756328202007135 [pii]
. HaczynskiJJakimiukA: Vertebral fractures: a hidden problem of osteoporosis. Med Sci Monit. 7:1108–1117, 2001. 1911 [pii]
16.
. HasselmanCTVogtMTStoneKL: Foot and ankle fractures in elderly white women. Incidence and risk factors. J Bone Joint Surg Am. 85-A:820–824, 2003.
17.
. HeaneyRPDaviesKMChenTC: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 77:204–210, 2003.
18.
. HollisBW: Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 135:317–322, 2005. 135/2/317 [pii]
19.
. JudeEBSelbyPLBurgessJ: Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 44:2032–2037, 2001.http://dx.doi.org/10.1007/s001250100008
20.
. KamelHK: Postmenopausal osteoporosis: etiology, current diagnostic strategies, and nonprescription interventions. J Manag Care Pharm. 12:S4–9; quiz S26–28, 2006. 2006(12)6:4–9 [pii]
21.
. KatesSLKatesOSMendelsonDA: Advances in the medical management of osteoporosis. Injury. 38Suppl 3:S17–23, 2007. S0020-1383(07)00318-X [pii] http://dx.doi.org/10.1016/j.injury.2007.08.007
22.
. KurlandESHellerSLDiamondB: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos Int. 15:992–997, 2004. 10.1007/s00198-004-1636-z
23.
. LaneJMNydickM: Osteoporosis: current modes of prevention and treatment. J Am Acad Orthop Surg. 7:19–31, 1999.
. LaneNEKelmanA: A review of anabolic therapies for osteoporosis. Arthritis Res Ther. 5:214–222, 2003. 10.1186/ar797
26.
. LewieckiEM: Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am. 35:301–315, ix, 2008. S0889-8545(08)00024-7 [pii] 10.1016/j.ogc.2008.03.007
27.
. LindsayRScheeleWHNeerR: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 164:2024–2030, 2004. 164/18/2024 [pii] http://dx.doi.org/10.1001/archinte.164.18.2024
28.
. McClungMRSan MartinJMillerPD: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 165:1762–1768, 2005. 165/15/1762 [pii] 10.1001/archinte.165.15.1762
29.
. McCormickRK: Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev. 12:113–145, 2007.
30.
. Munoz-TorresMAlonsoGRayaMP: Calcitonin therapy in osteoporosis. Treat Endocrinol. 3:117–132, 2004.
31.
. NeerRMArnaudCDZanchettaJR: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344:1434–1441, 2001. MJBA-441904 [pii]
32.
. OrwollESScheeleWHPaulS: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 18:9–17, 2003.
33.
. PitoccoDRuotoloVCaputoS: Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 28:1214–1215, 2005. 28/5/1214 [pii]
34.
. RossouwJEAndersonGLPrenticeRL: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333, 2002. joc21036 [pii]
. StroupJKaneMPAbu-BakerAM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 65:532–539, 2008. 65/6/532 [pii] http://dx.doi.org/10.2146/ajhp070171
37.
. US Department of Health and Human Services, Office of the Surgeon General. Bone health and osteoporosis: a report of the surgeon general. Rockville (MD). 2004.
